# CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

> **NCT03289455** · PHASE1,PHASE2 · COMPLETED · sponsor: **Autolus Limited** · enrollment: 23 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Refractory Childhood Acute Lymphoblastic Leukemia
- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** AUTO3 (CD19/22 CAR T cells

## Key facts

- **NCT ID:** NCT03289455
- **Lead sponsor:** Autolus Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2020-05-18
- **Final completion:** 2020-05-18
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289455, "CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03289455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*